Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) EPS (Weighted Average and Diluted) (2016 - 2024)

Apyx Medical's EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at -$0.19 for Q2 2024.

  • For Q2 2024, EPS (Weighted Average and Diluted) fell 533.33% year-over-year to -$0.19; the TTM value through Jun 2024 reached -$0.82, down 74.47%, while the annual FY2023 figure was -$0.54, 19.4% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.19 in Q2 2024 per APYX's latest filing, up from -$0.22 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.03 in Q2 2023 to a low of -$0.28 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.14, with a median of -$0.14 recorded in 2020.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 81.25% in 2023, then plummeted 533.33% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.05 in 2020, then decreased by 20.0% to -$0.06 in 2021, then tumbled by 183.33% to -$0.17 in 2022, then crashed by 64.71% to -$0.28 in 2023, then surged by 32.14% to -$0.19 in 2024.
  • Per Business Quant, the three most recent readings for APYX's EPS (Weighted Average and Diluted) are -$0.19 (Q2 2024), -$0.22 (Q1 2024), and -$0.28 (Q4 2023).